Factor Xa inhibitors: a novel therapeutic class for the treatment of nonvalvular atrial fibrillation.

about

New frontiers in anticoagulation: non vitamin-K oral anticoagulants in stroke prevention.

P2860

Q39027027-DFA53239-CD91-40A3-98DD-EF35C178D454

P2860

Factor Xa inhibitors: a novel therapeutic class for the treatment of nonvalvular atrial fibrillation.

Item

http://www.wikidata.org/entity/Q38588261

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Factor Xa inhibitors: a novel ...... nvalvular atrial fibrillation.

@en

type

Item

label

Factor Xa inhibitors: a novel ...... nvalvular atrial fibrillation.

@en

prefLabel

Factor Xa inhibitors: a novel ...... nvalvular atrial fibrillation.

@en

P1476

Factor Xa inhibitors: a novel ...... nvalvular atrial fibrillation.

@en

P2093

April Robinson

http://www.w3.org/2001/XMLSchema#string

Delilah McCarty

http://www.w3.org/2001/XMLSchema#string

P2860

New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness

Practical management of anticoagulation in patients with atrial fibrillation

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects

Epidemiology of atrial fibrillation: European perspective

2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society

2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

Apixaban versus warfarin in patients with atrial fibrillation

Edoxaban versus warfarin in patients with atrial fibrillation

Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.

P304

37-49

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1753944715605011

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-09-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26378211

http://www.w3.org/2001/XMLSchema#string

P932

5933600

http://www.w3.org/2001/XMLSchema#string

Factor Xa inhibitors: a novel therapeutic class for the treatment of nonvalvular atrial fibrillation.

about

P2860

P2860

Factor Xa inhibitors: a novel therapeutic class for the treatment of nonvalvular atrial fibrillation.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932